Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab plus chemotherapy) Meeting Abstract
| Authors: | Chan, J. A.; Raj, N. P.; Aggarwal, R. R.; Calabrese, S.; DeMore, A.; Dhawan, M. S.; Fattah, D.; Fong, L.; Grabowsky, J.; Hope, T. A.; Kolli, K. P.; Munster, P. N.; Perez, K.; Reidy, D. L.; Von Fedak, S.; Zhang, L.; Bergsland, E. K. |
| Abstract Title: | Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab plus chemotherapy) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120602248 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.4148 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4148 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work